600594 益佰制药
2024/09 - 九个月2023/122022/122021/122020/12

盈利能力分析
净资产收益率 ROE (%)-6.1153.599-14.1407.4726.632
总资产报酬率 ROA (%)-3.8602.227-9.1374.8994.184
投入资产回报率 ROIC (%)-4.4032.563-10.4745.5324.714

边际利润分析
销售毛利率 (%)62.19669.47170.96378.75478.995
营业利润率 (%)-9.5384.870-13.7459.4249.256
息税前利润/营业总收入 (%)-9.1985.245-13.11610.1829.717
净利润/营业总收入 (%)-10.1673.239-16.4426.8965.932

收益指标分析
经营活动净收益/利润总额(%)74.242150.494-53.505144.023145.373
价值变动净收益/利润总额(%)-0.0840.0220.04211.161-1.423
营业外收支净额/利润总额(%)5.925-3.8074.107-1.624-6.208

偿债能力分析
流动比率 (X)1.9982.2261.7401.5931.487
速动比率 (X)1.3601.5951.2071.0801.163
资产负债率 (%)33.36534.34735.83930.75434.883
带息债务/全部投入资本 (%)20.98621.84125.13720.30525.965
股东权益/带息债务 (%)344.946328.028281.679379.863273.746
股东权益/负债合计 (%)190.455182.676170.342221.220181.115
利息保障倍数 (X)-9.7719.479-10.76911.2099.700

营运能力分析
应收账款周转天数 (天)36.77133.28641.81435.37632.212
存货周转天数 (天)237.426253.296267.364266.560228.196